TEL: 044-952-0102


Combination Inhalers for Upper Airway Diseases

発行 Greystone Research Associates 商品コード 337817
出版日 ページ情報 英文
納期: 即日から翌営業日
本日の銀行送金レート: 1USD=111.05円で換算しております。
Back to Top
上気道疾患向けコンビネーション吸入薬市場 Combination Inhalers for Upper Airway Diseases
出版日: 2015年08月24日 ページ情報: 英文
Greystone Research AssociatesはDDSを専門とする調査会社でDDSの細かなテーマを選びそれぞれ独立したレポートとして発行していることが特徴です。本レポートでは喘息、COPDを対象とするコンビネーションプロダクトを対象としています。製剤開発に影響を与える技術的要因、吸入形態別の製品分析、開発中のコンビネーションプロダクトなどをまとめています。市場に影響する要因をそれぞれ取り上げて論じているため、レポートの内容を自社に当てはめて考えることが可能です。

使いやすさ、および多くの患者にとって上気道疾患に関連した症状の管理が改善したことから、 コンビネーション吸入薬の開発活動および製品普及は大幅に増加しています。コンビネーション吸入薬は主に吸入コルチコステロイドと気管支拡張剤の組み合わせで構成されています。これらの製品は、2020年代後半に大幅に増加すると予測される2つの市場 - 喘息およびCOPD (慢性閉塞肺疾患) の市場で大きな商業的成功を収めています。

当レポートでは、コンビネーション (併用) 経口吸入薬の市場について調査し、複数の薬剤を送達する経口吸入器技術、製品の技術課題と発展する市場要因、開発段階にある併用療法吸入薬と市場投入スケジュール、吸入薬メーカーとそのアライアンスパートナーに対する経済・技術・規制要因の影響などについて分析しており、コンビネーション吸入薬の市場データと予測、および主要企業のプロファイルなどをまとめ、お届けいたします。



  • 上気道治療薬市場
  • コンビネーション吸入薬の治療ターゲット
  • 競合する治療薬
  • 需要の促進因子
  • 技術要因
  • 競合情勢


  • 世界の患者統計
  • 地域市場の促進因子
  • 治療ニーズの拡大


  • ドライパウダー吸入器 (DPI)
    • DPI処方技術
    • 特徴・パラメーター
    • DPI賦形剤・パッケージング
  • 定量吸入器 (MDI)
    • MDI装置の選定基準
    • 使いやすさの要素
  • ネブライザー


  • Albuterol/Ipratropium (ネブライザー)
  • Albuterol/Ipratropium (MDI)
  • Generic Albuterol/Ipratropium Solution
  • Fluticasone/Vilanterol (DPI)
  • Fluticasone/Salmeterol (MDI)
  • Fluticasone/Salmeterol (DPI)
  • Budesonide/Formoterol (MDI)
  • Formoterol/Mometasone (MDI)
  • Umeclidinium/Vilanterol (DPI)


  • ドライパウダー処方薬
  • 定量処方薬
  • ネブライザー投与ソリューション


  • 喘息
    • 需要要因
    • 地域的な市場影響要因
  • COPD


  • 法規制上の課題
  • 患者服薬コンプライアンス
  • 処方動向
  • 医療経済学
  • 地域的な市場影響要因
  • コネクテッドデバイス


Product Code: DHJ554F

Analyzing the Growth of Dual Therapy Inhalers

Combination inhalers - oral inhalers containing two drugs that complement the therapeutic actions of one another - have seen a significant increase in development activity and product proliferation in the past five years. Growth is being driven by improved patient experience as derived from ease-of use (fewer devices/medications to administer) and for many patients improved control of symptoms associated with upper airway diseases. Combination inhalers most commonly consist of an inhaled corticosteroid in combination with a bronchodilator. These products are realizing significant commercial success in the two markets for which they are indicated - Asthma and COPD - both of which are forecast to grow at impressive rates for the remainder of the decade.

The value we provide to our clients and subscribers is best illustrated by our ability to consistently provide strategic direction and market knowledge that contributes to their tactical and strategic decision process.

Market-driven Product Strategies

A longer life span is expected to translate to a growing number of patients diagnosed with chronic conditions. To counteract the financial and medical infrastructure implications of this trend, pressure from the public sector and managed care organizations will place a premium on therapeutic self-administration, an expectation that is creating an increased interest in routes of administration that are patient-friendly and cost-effective. Pharma company decision makers have come to the realization that for many products, success no longer only depends on the medication itself but also on achieving a consumer-compatible form of packaging and application.

‘The upper airway diseases Asthma and COPD remain significant health challenges for both patients and clinicians. Inhalers that combine two drugs indicated for treating upper airway diseases in one inhaler are gaining interest due to the complementary therapeutic effects of certain classes of drugs when taken together. The current trend in asthma and COPD inhaler evolution has seen an increase in the incorporation of ergonomic features by device designers aimed at increasing patient receptiveness. Recent inhaler designs have approached the goals of improved usability and patient adherence from a number of distinct directions, including dose preparation technology, dose packaging, novel formulation technology, dosing confirmation, and symptoms monitoring.’

Our reports are carefully researched and written to provide timely and insightful analysis of key factors and developments shaping the commercial marketplace. The focused nature of our publications is designed to allow readers to identify emerging demand and growth opportunities in selected markets. Numerous charts, tables and graphs complement the text, with evaluations and assessments of current and probable future market developments, technology issues and business factors - information necessary to compete effectively in the global marketplace.

Report Highlights

  • Analyzes the market for combination (dual drug) oral inhalers
  • Assesses oral inhalation device technology for delivering multiple drugs, and evaluates product technology issues and evolving market factors
  • Provides detailed assessments of combination drug inhalers, their growth prospects and market potential
  • Evaluates development-stage dual therapy inhalers and assesses likely market entry timelines
  • Provides market data and forecasts for dual drug oral inhaler products to 2022
  • Profiles inhaled drug product market participants, their technology, product development activity, and business strategies
  • Evaluates the impact of economic, technology, and regulatory factors on inhaled drug companies and their alliance partners

Table of Contents

Executive Summary

Orally Inhaled Corticosteroid Market Overview

  • The Upper Respiratory Therapeutics Marketspace
  • Therapeutic Targets for Combination Inhalers
  • Competing Drug Treatments
  • Demand Drivers
  • Technology Factors
  • Competitive Landscape

Asthma Market Risks and Opportunities

  • Global Patient Demographics
  • Regional Market Drivers
  • The Growing Therapeutic Need

Inhaler Technologies for Delivering Combination Therapies

  • Dry Powder Inhalers
    • DPI Formulation Technology
    • Characteristics and Parameters
    • DPI Excipients and Packaging
  • Metered Dose Inhalers
    • MDI Device Selection Criteria
    • Ease-of-Use Factors
  • Nebulizers

Combination Inhalers - Product Analysis, Market Data & Forecasts

  • Albuterol/Ipratropium (Nebulizer)
  • Albuterol/Ipratropium (MDI)
  • Generic Albuterol/Ipratropium Solution
  • Fluticasone/Vilanterol (DPI)
  • Fluticasone/Salmeterol (MDI)
  • Fluticasone/Salmeterol (DPI)
  • Budesonide/Formoterol (MDI)
  • Formoterol/Mometasone (MDI)
  • Umeclidinium/Vilanterol (DPI)

Development-stage Combination Inhalers

  • Dry Powder Formulations
  • Metered Dose Formulations
  • Nebulized Solutions

Therapeutic Market Assessment

  • Asthma
    • Demand Factors
    • Regional Market Factors
  • COPD
    • Demand Factors
    • Regional Market Factors

Market Factors

  • Regulatory Issues
  • Patient Compliance
  • Prescribing Trends
  • Healthcare Economics
  • Regional Market Factors
  • Connected Devices

Market Sector Company Profiles

Back to Top